<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953420</url>
  </required_header>
  <id_info>
    <org_study_id>25145-CADEN</org_study_id>
    <secondary_id>CADEN</secondary_id>
    <nct_id>NCT00953420</nct_id>
  </id_info>
  <brief_title>Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes</brief_title>
  <acronym>CADEN</acronym>
  <official_title>Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come
      back or not gone away after the best known standard treatments.

      Most patients that respond to chemotherapy once their NPC tumors have come back have been
      treated with a platinum-based medication like cisplatin. However, since many patients are
      given cisplatin during their initial treatment for NPC, in this study, they will be treated
      with another platinum-based chemotherapy medicine that has been used in patients with NPC
      called carboplatin. In this study, carboplatin will be used in combination with another drug
      called docetaxel. Other studies in patients with advanced head and neck cancer have shown
      that docetaxel can cause tumors to respond better and allow patients to survive longer when
      added to the standard treatments for those diseases.

      Some patients with NPC show evidence of infection with the virus that causes infectious
      mononucleosis, known as the Epstein Barr virus (EBV), before or at the time of their cancer
      diagnosis. EBV is found in the cancer cells of almost all patients with advanced stage
      disease, suggesting that it may play a role in causing NPC. Previously, patients have been
      treated with high-risk NPC using EBV-specific cytotoxic T cells. These cells are grown in the
      laboratory and taught to recognize and attack EBV infected cells. In the past, patients were
      either given the cells alone or just after they had received a medication to briefly lower
      their white blood cell count. In both cases, many patients had their tumors shrink and in
      some cases completely disappear after being treated with these EBV-specific cytotoxic T
      cells.

      Investigators have now decided to look at how patients with NPC and their tumors respond to
      the treatment combination of chemotherapy and EBV-CTL. Patients are being asked to
      participate in this study since the NPC tumor is associated with EBV and has either come back
      or not responded to standard treatment. This combination of chemotherapy and EBV-CTLs is an
      investigational treatment not approved by the Food and Drug Administration.

      The purpose of this study is to see how relapsed or refractory, EBV-associated NPC tumors
      respond when treated with carboplatin and docetaxel followed by EBV-CTL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A blood sample will be obtained to start making the CTLs before the patient begins
      chemotherapy. The patients EBV-specific T cells will be grown while the patient is being
      treated with chemotherapy and given back to the patient after their chemotherapy is
      completed.

      To prepare the CTLs, 60-70 cc of blood will be taken from the patient. The amount of blood
      collected depends on their size and weight, no more than 3 cc of blood per kg of body weight
      will be collected at any one time.

      This blood will be used to grow an EBV-infected B-cell line and then a T-cell line. B cells
      and T cells are types of white blood cells that help fight infections in the body. After
      growing T cells in the laboratory, these cells will be stimulated with EBV infected B cells.
      The B cells have been treated with radiation so they cannot grow; however, they can provide
      the stimulation that will train the T cells to recognize and kill EBV infected cells.

      The generation of EBV-CTL requires the use of a special cell line, called lymphoblastoid cell
      line, which will be made from the blood by infecting cells with EBV. Once the LCLs are made,
      the T cells will be repeatedly stimulate with the LCLs to make EBV-CTL.

      The CTLs will then be tested to make sure they kill the EBV infected cells before they are
      given back to the patient. If the number of CTLs produced is low, investigators may need to
      obtain additional blood samples to make these cells.

      Because the patients cells are being grown in the laboratory, blood will have to be taken to
      test for infectious viruses such as hepatitis and HIV and patients will also have to fill in
      a questionnaire that is given to standard blood donors.

      EXPECTED LENGTH OF STUDY The chemotherapy treatment portion is planned as 4 cycles of
      chemotherapy given every 3 weeks. Up to an additional 2 cycles of chemotherapy may be given
      if the EBV-CTL product is not available after the initial 4 cycles.

      If the patient has been able to complete at least 4 cycles of chemotherapy and the EBV-CTL
      are ready for infusion,then the cells will be given back to the patient. The infusion of the
      T cells will last about 1 to 5 minutes after the patient has been pretreated with one dose of
      Tylenol and Benadryl.

      The patient will have another disease re-evaluation 8 weeks after the first EBV-CTL
      injection. Based upon the patient's response to the first infusion, the patient may receive
      extra doses of cells if they are available. These would be given every 1.5-3 months. If the
      patient has additional injections of cells, this will require an additional disease
      re-evaluation 8 weeks after each infusion.

      To learn more about the way the EBV-CTLS are working and how long they last in the body,
      10-60 mls of blood will be taken before and after each infusion. Up to 60 ml of blood will
      also be drawn before each cycle of chemotherapy that occurs at Week 1, Week 4, Week 7, Week
      10 before the T cell infusion and then at Weeks 1, 2, 4, 6 and 8 weeks after infusion, and
      then again at the follow-up visits 5, 8, and 11-12 months after infusion. This blood will be
      used to look at the immune response to the patient's cancer. If the patient only has one
      EBV-CTL infusion, up to 108 teaspoons of blood will be drawn to allow for evaluation of his
      or her response to treatment; however, the total amount of blood collected on this study will
      depend on the total number of EBV-CTL infusions that the patient has.

      The patient and his/her response to therapy will be followed for at least 1 year after
      treatment on this study ends.

      STUDY TREATMENT While the cells are being grown, the patient will be started on chemotherapy
      in order to shrink the size and/or amount of his/her tumor.

      The patient will be treated with a combination of docetaxel and carboplatin chemotherapy. The
      chemotherapy will be given outpatient over several hours. Docetaxel can cause the body to
      hold on to extra fluid (fluid retention). This side effect can be prevented in most people if
      they take a small steroid dose before and after docetaxel is given. Therefore, the night
      before and on the morning chemotherapy is to start, the patient will take a steroid called
      dexamethasone by mouth.

      Once the patient gets to clinic, he/she will be given a dose of docetaxel and then a dose of
      carboplatin. Each of these medications will be given into the vein after an IV is placed or
      into the central line. The patient will then take the last dose of dexamethasone before going
      to bed that night. The patient will receive chemotherapy treatment once every 21 days as long
      as the patient's blood counts and laboratory tests have returned to an acceptable level. The
      patient will have a re-evaluation of his/her disease with imaging scans and laboratory tests
      after the second round of chemotherapy. If the patient's tumor has not gotten worse and/or
      has not had severe side effects from the chemotherapy, the patient will be treated with 2 to
      4 additional rounds of chemotherapy while we are waiting for the EBV-CTLs to be finished.

      The combination of chemotherapy agents used in this study might cause the patient's white
      blood cells to be low. If they are low for a long period of time or the patient develop a
      serious infection while they are low, her/she may be given an extra medication called
      Granulocyte colony-stimulating factor (GCSF). GCSF helps to stimulate the production of white
      blood cells. However, it is anticipated that most people on the study will not require GCSF.

      Once the EBV-CTLs are ready and the patient has recovered from the last round of
      chemotherapy, the EBV-CTL infusion will be scheduled. The CTL infusion will take place at
      either Houston Methodist Hospital or Texas Children's Hospital. The CTL infusion takes about
      1 to 5 minutes, but patients are typically monitored for up to 4 hours after the infusion to
      make sure that he/she does not have a reaction to the cells.

      END OF TREATMENT AND FOLLOW-UP

      The patient will have a number of tests and procedures as part of follow up to treatment.
      These tests will be used to watch for improvements in tumor size, monitor for side effects
      from the treatment, evaluate how the T cells are working, and look for any signs that the
      cancer has come back. The patient's will have a physical exam and standard lab tests,
      including blood tests, and imaging studies about every 3 months during the first year after
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study is to evaluate the overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy and immunotherapy.</measure>
    <time_frame>3 months</time_frame>
    <description>The overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy (treatment with docetaxel and carboplatin) followed by immunotherapy with EBV-specific Cytotoxic T lymphocytes will be measured. Response rates will be estimated as the percent of patients whose best response is a CR or PR, and a 95% confidence interval will be calculated for the fraction of responses obtained.To measure the overall response rate, disease will be determined by imaging (MRI, CT, and/or PET imaging) 8 weeks after immunotherapy. In addition, per standard of care, disease re-evaluation will continue 3 months during the first year after participation and then as clinically indicated per the patient's primary oncologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to re-induction chemotherapy</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immune response by measuring EBV-DNA levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m2 IV on Day 1
Carboplatin with target AUC of 5 (mg/ml x min) on Day 1
Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
After cycle 1, subsequent cycles of chemotherapy may start once ANC &gt; 1000 and platelets &gt; 100,000 post nadir
Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>60 mg/m2 IV on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Target AUC of 5 (mg/ml x min) on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EBV-specific cytotoxic T lymphocytes</intervention_name>
    <description>1 x 10e8 cells/m2 IV over 1 to 5 min</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>EBV-specific cytotoxic T lymphocytes 1 x 10e8 cells/m2 IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>G-CSF or Peg-GCSF</intervention_name>
    <description>If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg â‰¤ 45 kg; 6 mg for &gt; 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC &gt; 2500 cells/ul x 2 days after nadir.</description>
    <arm_group_label>Chemotherapy and Immunotherapy</arm_group_label>
    <other_name>Filgrastim or pegylated filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory
             disease in whom the EBV-genome or antigens have been demonstrated in tissue biopsy
             samples

          -  Age 10 years or older

          -  Life expectancy of 8 weeks or more

          -  Karnofsky or Lansky score of 50 or more

          -  Normal bilirubin level (per institutional standard)

          -  AST and ALT 1.5 x or less upper limit of normal

          -  Alk Phos level less than 2.5 x upper limit of normal

          -  ANC greater than 1500 cells/ul

          -  Hgb 8.0 or greater

          -  Platelets 100,000 cells/ul or more

          -  Creatinine 2 x or less ULN or GFR 50 ml/min/1.73 m2 or more

          -  Women of child-bearing potential must take/use effective birth control while
             participating in the study.

        EXCLUSION CRITERIA:

          -  Due to the unknown effects of this therapy on a fetus, pregnant women will be excluded
             from this research.

          -  Prior allergic reaction to the study drugs used in this protocol or other drugs
             formulated with polysorbate 80.

          -  Known HIV positive subjects since treatment may be significantly immunosuppressive

          -  Women who are breast-feeding

          -  Severe intercurrent infection

          -  Patients, who in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystal U Louis, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Children's Hospital; Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <disposition_first_submitted>August 26, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2015</disposition_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Chrystal Louis</investigator_full_name>
    <investigator_title>Assistant Professor Pediatrics-Hem-Onc Cell &amp; Gene</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Epstein-Barr Virus</keyword>
  <keyword>T Lymphocytes</keyword>
  <keyword>EBV-CTLs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

